Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion (X-VERT)
This study has been completed.
First Posted: August 29, 2012
Last Update Posted: April 30, 2015
Janssen Research & Development, LLC
Information provided by (Responsible Party):